Estimation of adherence to urate-lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient-reported dosing.

Marcel Schulz Matthew James Coleshill Richard Osborne Day Daniel F B Wright Jonathan Brett Nancy E Briggs Eindra Aung

Published in: British journal of clinical pharmacology (2024)

Participant-reported allopurinol daily doses, in addition to PBS dispensing claims, may enhance confidence in estimating PDC and adherence compared to using DDD. This approach improves adherence estimations from pharmaceutical claims datasets for medications where daily doses vary between individuals or where there is a wide therapeutic dose range.

Keyphrases

patient reported
health insurance
physical activity
glycemic control
type diabetes
mesenchymal stem cells
metabolic syndrome
skeletal muscle
insulin resistance